• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Weekly insulin efsitora alfa is non-inferior to daily insulin degludec for reducing HbA1c in type 1 diabetes

byNeel MistryandTeddy Guo
October 9, 2024
in Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 2 mins read
Diabetes and insulin collage: a calm woman beside a pancreas drawing, an islet cell inset and glucose test strips
Share on FacebookShare on TwitterShare on LinkedIn

1. Once weekly efsitora demonstrated non-inferiority compared with degludec with regards to change in HbA1c.

2. Patients in the efsitora group reported greater hypoglycemic events than those assigned to once daily degludec.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Insulin efsitora alfa is a weekly basal insulin that may be more convenient than current daily insulin regimens. Insulin degludec is an established daily insulin treatment, and comparisons between these options are crucial to understanding the efficacy and safety of efsitora. This randomized controlled trial aimed to evaluate whether once-weekly efsitora is as effective as daily degludec in controlling blood glucose levels in adults with type 1 diabetes. The primary outcome was mean change in HbA1c from baseline to week 26, while a key secondary outcome was the incidence of hypoglycemic events. According to study results, efsitora was non-inferior to degludec in reducing HbA1c but demonstrated increased rates of hypoglycemia. Although this study was well done, it was limited by a high incidence of hypoglycemia in the efsitora group, which may require further investigation into dosing and optimization strategies.

Click to read the study in The Lancet

Relevant Reading: Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

RELATED REPORTS

2MM: Pharma Roundup – First DNA therapy approved which could reduce airway surgeries, novel siRNA targets dual lipid pathways, GLP-1s outperform metformin in prediabetes, and Zolgensma tumor risks under FDA review

Deep-learning model achieved high diagnostic performance for diabetic macular edema detection using optical coherence tomography (OCT) scans

Drug pageOnswik (insulin efsitora alfa-gobe), approved Sep 23, 2026. Indication, pivotal trial and safety at a glance.→

In-depth [randomized-controlled trial]: Between Aug 12, 2022, and May 7, 2024, 893 patients were assessed for eligibility across 82 centers in 6 countries. Included were patients ≥ 18 years with type 1 diabetes and HbA1c between 7.0-10.0%. Altogether, 692 patients (343 in once weekly efsitora group and 349 in once daily degludec group) were included in the final analysis. The primary outcome of mean change in HbA1c was non-inferior for efsitora compared to degludec (7.88% at baseline to 7.41% at week 26 with efsitora, mean adjusted change [MAC] -0.51% vs. 7.94% at baseline to 7.36% with degludec, MAC -0.56%). The secondary outcome of severe hypoglycemia events was higher in the efsitora group than degludec (14.03 vs. 11.59, rate ratio [RR] 1.21, p=0.016). Findings from this study suggest that efsitora may be effective in reducing HbA1c similar to degludec.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: diabetesendocrinologyglucose controlhypoglycemiainsulininsulin degludecinsulin efsitora alfatype 1 diabetesType 1 Diabetes Mellitus
Previous Post

Fidanacogene elaparovovec may reduce bleeding in men with hemophilia B

Next Post

#VisualAbstract Screening for Helicobacter Pylori to Prevent Gastric Cancer with Fecal Immunochemical Tests

RelatedReports

A variety of pharmaceutical items including a vial, capsule, molecule model, pill blister pack, petri dish with a pipette, and a graph, symbolizing drug development.
Pharma Roundup

2MM: Pharma Roundup – First DNA therapy approved which could reduce airway surgeries, novel siRNA targets dual lipid pathways, GLP-1s outperform metformin in prediabetes, and Zolgensma tumor risks under FDA review

November 9, 2026
A glucose meter, a droplet of liquid, and abstract representations of data and research materials, symbolizing diabetes management and detection methods.
Endocrinology

Deep-learning model achieved high diagnostic performance for diabetic macular edema detection using optical coherence tomography (OCT) scans

September 10, 2026
Eye disease collage: an engraved slit-lamp microscope casting a pale beam, with folded reading glasses on graph paper
Chronic Disease

Cataract surgery is associated with increased incidence of diabetic retinopathy among patients with diabetes

September 8, 2026
Physical activity collage: a smiling middle-aged man in a track jacket beside a city bicycle and a teal resistance band
Chronic Disease

A healthy lifestyle may reduce risk of infection in patients with type 2 diabetes

September 2, 2026
Next Post
#VisualAbstract Screening for Helicobacter Pylori to Prevent Gastric Cancer with Fecal Immunochemical Tests

#VisualAbstract Screening for Helicobacter Pylori to Prevent Gastric Cancer with Fecal Immunochemical Tests

Admission may not be needed following sleep apnea surgery

Tirzepatide reduces obstructive sleep apnea symptoms and associated risks

Extended lymphadenectomy does not improve survival in muscle-invasive bladder cancer

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gait analysis predicts health, sleep, and medication use across 18 body systems
  • Bariatric surgery associated with lower obesity-related cancer incidence in Nordic cohort
  • Cretostimogene reduced recurrence risk in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer in topline phase 3 results
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.